RPS urges community pharmacists to take up free post-registration training

RPS urges community pharmacists to take up free post-registration training

February 22 2018 Community pharmacists in England are being urged to enrol on Masters level...

Which? report claims 'three in 10 pharmacies not following safety guidelines'

Which? report claims 'three in 10 pharmacies not following safety guidelines'

  February 20 2018 A covert study of pharmacies has claimed that some pharmacies are...

British Lung Foundation issues pharmacy resources

British Lung Foundation issues pharmacy resources

February 20 2018 Two new guides supporting the role of community pharmacists in helping patients...

CPPE announces patient safety learning campaign

CPPE announces patient safety learning campaign

February 19 2018 Pharmacists should be receiving educational material this week on a new patient...

Social media engagement training for pharmacists on offer in Northern Ireland

Social media engagement training for pharmacists on offer in Northern Ireland

February 16 2018 Pharmacy Forum NI is hosting a training evening on getting the most out of...

  • RPS urges community pharmacists to take up free post-registration training

    RPS urges community pharmacists to take up free post-registration training

    Thursday, 22 February 2018 16:05
  • Which? report claims 'three in 10 pharmacies not following safety guidelines'

    Which? report claims 'three in 10 pharmacies not following safety guidelines'

    Tuesday, 20 February 2018 17:04
  • British Lung Foundation issues pharmacy resources

    British Lung Foundation issues pharmacy resources

    Tuesday, 20 February 2018 16:34
  • CPPE announces patient safety learning campaign

    CPPE announces patient safety learning campaign

    Monday, 19 February 2018 17:29
  • Social media engagement training for pharmacists on offer in Northern Ireland

    Social media engagement training for pharmacists on offer in Northern Ireland

    Friday, 16 February 2018 18:06

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a pharmacist consulting with patientFebruary 9 2018

Precautions around the use of dopaminergic drugs in Parkinson’s disease are included in a new NICE Quality Standard. 

One of the five quality statements in QS 164 says that patients receiving dopaminergic therapy should be given advice about the risk of developing impulse control disorders. The quality statement has been included as “dopaminergic therapy, especially with dopamine agonists, is associated with a risk of developing impulse control disorders,” says NICE.

“It is important to discuss this risk and provide information to adults with Parkinson’s disease, and their family members and carers, when starting treatment and at least annually. This will help them to recognise the symptoms and know where to get help if these develop.”

NICE expects healthcare professionals to “provide oral and written information about the risk of developing impulse control disorders to adults with Parkinson’s disease when starting dopaminergic therapy (not just dopamine agonists) and discuss this with them at least annually.” Health professionals should also provide information for family members and carers if appropriate.

In addition, “oral and written information should be given about:

  • the different types of impulse control disorders (for example, compulsive gambling, hypersexuality, binge eating and obsessive shopping);
  • the increased risk of impulse control disorders developing with dopamine agonists;
  • the risk that impulse control disorders may be concealed by the person affected;
  • who to contact if impulse control disorders develop;
  • the possibility that if problematic impulse control disorders develop, dopamine agonist therapy will be reviewed and may be reduced or stopped.”

QS 164 also includes quality statements around the administration of levodopa in care settings. It says adults with Parkinson’s disease who are in hospital or a care home should be taking levodopa within 30 minutes of their individually prescribed administration time. This means that adults with Parkinson’s disease will need to “have an accurate medicines chart that reflects timings for levodopa before admission,” it says.

“Practitioners should support adults with Parkinson’s disease to take levodopa on time, which may include self-medication. Practitioners should report any medicines-related patient safety incidents for adults with Parkinson’s disease.”

A further quality statement says patients should have access to clozapine and patient monitoring for treating hallucinations and delusions.

The Quality Standard should be used alongside NICE guideline NG71 on Parkinson’s disease in adults.

Links:
NICE QS 164 Parkinson’s Disease          
NICE Guideline on Parkinson’s disease in adults NG71   

Practice News

February 22 2018 Community pharmacists in England are being urged to enrol on Masters level training modules with costs covered by the Pharmacy Integration Fund.
February 19 2018 Pharmacists should be receiving educational material this week on a new patient safety campaign from the Centre of Pharmacy Postgraduate Education. Resources have been mailed out ahead...